📍#CLINICAL24 Feature
A new chapter in brain health and Alzheimer's disease diagnostics
Advances in laboratory neurology are transforming our understanding of brain health, opening new possibilities for the earlier detection, diagnosis, and management of Alzheimer's disease and other forms of dementia. As part of #CLINICAL24, SelectScience brings together leading clinicians, researchers, laboratory professionals, patient advocates, and industry experts to explore the latest developments in dementia science and neurological testing. From the discovery and validation of novel blood-based biomarkers to advances in imaging, genomics, multi-omics, and digital health technologies, experts discuss how innovation is reshaping the pathway to diagnosis and care.
Explore emerging research into disease mechanisms, risk prediction, prevention strategies, and therapeutic interventions, alongside the practical considerations of implementing new tests in clinical laboratories. Discover the expert insights, scientific breakthroughs, and laboratory innovations helping to advance precision medicine in neurology, support earlier and more accurate diagnoses, improve patient access to care, and shape a new chapter in brain health for individuals affected by Alzheimer's disease and other neurodegenerative conditions.
CLINICAL24 Forum: Exploring new biomarkers beyond pTau217 for Alzheimer’s disease
Sponsored by Spear Bio
Discover how emerging blood-based biomarkers could transform Alzheimer’s disease detection, staging and monitoring. This expert forum examines the clinical potential and limitations of pTau217, eMTBR-Tau and multi-biomarker approaches, alongside remote testing, PET imaging and AI, to explore more accessible, personalized diagnostic pathways for patients worldwide and improved treatment decisions globally.
The event is perfect for clinical laboratory professionals and academic researchers interested in Alzheimer’s disease biomarkers and tau biology.
Register now
Spear Bio expands Alzheimer’s biomarker portfolio with novel epTau 217 and eMTBR-Tau assays, supported by a fully automated workflow
Hear Oliver Tassinari of Spear Bio and Dr. Thomas Karikari of the University of Pittsburgh discuss innovative blood-based biomarkers for Alzheimer's disease research. Explore how novel epTau 217 and eMTBR-Tau assays, combined with automated workflows, could support more scalable, reproducible, and informative biomarker studies.
Watch video
Making Alzheimer’s testing more accessible with blood-based biomarkers
In this video, Dr. Chris Bird, Chief Medical Officer at Beckman Coulter Diagnostics, discusses the evolution of Alzheimer’s disease testing from PET imaging and cerebrospinal fluid analysis to the growing role of blood-based biomarkers. Bird explains how advances in analytical sensitivity, including the DxI 9000 Immunoassay Analyzer, could help detect highly diluted biomarker signals in blood and support more scalable approaches to assessing Alzheimer’s-related pathology.
Watch video
How pTau 217 and NfL blood-based biomarkers are reshaping diagnosis in Alzheimer’s and neurodegenerative disease
Blood-based biomarkers are revolutionizing the detection and monitoring of Alzheimer’s disease. In this expert interview, discover how markers such as pTau217 and NfL are improving diagnostic accuracy, supporting earlier intervention, and helping researchers and clinicians better understand disease progression.
Read articleThe brain health and Alzheimer's disease diagnostics community
Advances in brain health and Alzheimer's disease diagnostics are transforming how neurological conditions are understood, detected, and managed. From emerging biomarkers and blood-based testing to advances in laboratory neurology and dementia research, the field continues to evolve rapidly.
Stay connected with the latest expert insights, scientific developments, and educational content from across the brain health and dementia community.
Want the latest news, interviews, webinars, and resources delivered straight to your inbox? Become a member for free here.
Building a better approach to Alzheimer’s diagnosis
Learn how emerging biomarkers are transforming the diagnosis of Alzheimer’s disease and helping to drive a new era of precision neurology. Russ Lebovitz, MD, PhD, CEO and Co-Founder of Amprion discusses the latest advances in blood-based testing, the opportunities and challenges of early detection, and how innovative diagnostic approaches could improve clinical decision-making and patient care. Discover how biomarker science is reshaping the pathway from symptoms to diagnosis, enabling more accurate disease identification, supporting access to emerging therapies, and bringing us closer to faster, less invasive, and more accessible testing for Alzheimer’s disease.
Read article
Experts at AAIC 2026 discuss the changing Alzheimer’s care pathway
As Alzheimer’s disease becomes increasingly defined by biological markers rather than symptoms alone, the need for earlier, more scalable diagnostic approaches is growing. Dr. Gaby Marquardt, Siemens Healthineers, and Prof. Charlotte Teunissen, Alzheimer Center Amsterdam discuss how blood-based biomarkers could support earlier detection and broader access to Alzheimer’s diagnostics.
Watch video
How blood-based and plasma biomarkers are transforming clinical neurology
Professor Henrik Zetterberg, Professor of Neurochemistry at the University of Gothenburg, University College London, UK, and the University of Wisconsin–Madison, discusses how blood-based biomarkers and plasma biomarkers in neurology are advancing the detection, diagnosis, and monitoring of Alzheimer’s disease and other neurodegenerative diseases.
Watch video
Can biomarkers and AI transform traumatic brain injury care?
In this interview, Professor Frank Peacock explores how blood-based biomarkers and artificial intelligence could transform the diagnosis and management of traumatic brain injury (TBI).
Read article
Could a simple blood test transform Alzheimer’s diagnosis?
Dr. Ashton Harper, Global Medical Director for Neurosciences at Roche Diagnostics, discusses the current challenges in diagnosing Alzheimer’s disease and blood-based biomarkers such as pTau217.
Watch video
Advancing Alzheimer’s diagnostics at Quanterix with multi-marker testing
In this interview, Jorge Marquez, VP, Accelerator & Clinical Services at Quanterix, discusses the evolving role of blood-based biomarkers in Alzheimer’s disease detection and clinical decision-making.
Watch video
